# ALLANDER BIOTECHNOLOGIES, INC.: First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | ALLANDER BIOTECHNOLOGIES, INC. |
| Location | AURORA, CO |
| Project | First-in-human clinical trial of proprietary oral gel to treat radiation-induced oral mucositis in cancer patients |
| Project number | 5R44CA310522-02 |
| Mechanism | R44 |
| Institute | National Cancer Institute |
| Award | $1,066,148 |
| Awarded | 2026-09-14 |
| Project period | 2025-09-15 to 2027-08-31 |
| UEI | J8KMX54WRJM9 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11411493). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.